Topic resource collection
Approved comparison material connected to this topic.
4 resourcesRead both sides
BPC-157 Promotes angiogenesis via VEGF upregulation; accelerates soft tissue repair through fibroblast activation Phase 3 human trial (Nature Medicine Jan 2026): 42% faster healing vs placebo in 72-week study 98.8% (HPLC + third-…
Subcutaneous injection 80–95% 15–30 min 4–8 hours (sequence dependent) Requires reconstitution; injection site reaction risk Gold standard for most healing peptides. Bypasses first-pass metabolism entirely Intramuscular injection…
BPC-157 VEGF upregulation, FAK-paxillin activation, angiogenesis <5% (cleaved by pepsin) Phase II trials, no FDA approval 200–500 μg daily subcutaneous Strongest preclinical data for ulcer repair; limited large-scale human trials…
BPC-157 VEGF upregulation → angiogenesis Phase II diabetic ulcer trial: 42% faster healing vs standard care (University of Split, 2025) Topical or subcutaneous injection near injury site 5–7 days at 2–8°C once reconstituted Most …